Pheochromocytoma natural history, complications and prognosis

Revision as of 15:11, 31 July 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma natural history, complications and prognosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma natural history, complications and prognosis

CDC on Pheochromocytoma natural history, complications and prognosis

Pheochromocytoma natural history, complications and prognosis in the news

Blogs on Pheochromocytoma natural history, complications and prognosis

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Pheochromocytoma is an adrenaline secreting tumor, usually develop in the fifth decade of life. Symptoms start with tachycardia, hypertension, headache and sweating. Massive release of catecholamines can cause hyperglycemia, malignant hypertension and metastasis. The prognosis of pheochromocytoma is generally good but metastatic pheochromocytoma has a 5-year survival rate of approximately 50%[1]

Natural History, Complications and Prognosis

Natural History

  • Pheochromocytoma is the adrenaline secreting tumor, usually develop in the fifth decade of life.
  • Fifty percent of pheochromocytomas in children are solitary intra-adrenal lesions, 25% are present bilaterally, and 25% are extra-adrenal.
  • Most catecholamine-secreting tumors are sporadic.
  • However, 30% of patients got the tumor as a part of the familial disease, the catecholamine-secreting tumors are more likely to be bilateral.[2]

Symptoms start with tachycardia, hypertension, headache and sweating. If left untreated it causes hyperglycemia, hypertension emergency that causes heart failure, cerebrovascular strokes. If malignant, It can metastasize to lymph nodes, bones, lungs, and liver.

Complication

Other complications may include:

Prognosis

  • Pheochromocytoma prognosis is good if treated.
  • Approximately 10% recur after being resected.
  • Patients with metastatic pheochromocytoma five-year survival rates are approximately 50%.[1]Survival rate may depend on the primary tumor site and sites of metastases.
  • Tumor burden, the location of metastases, and rate of progression are the main factors affecting prognosis. Metastases in the brain, the liver has a worse prognosis than other metastases.
  • Prognosis of surgery
    • Good prognosis patients include small tumor size, short duration of surgery, systolic blood pressure less than 160 mmHg, and low levels of urinary catecholamines.[4]
    • Postoperative hypotension can be avoided by adequate fluid replacement.
    • Recurrence is more in patients with familial pheochromocytoma and extra-adrenal tumors.[5]
    • Familial pheochromocytomas have a high incidence of bilateral disease.
    • Partial adrenalectomy is recommended for these patients with bilateral pheochromocytomas to prevent permanent glucocorticoid deficiency.
    • Complete bilateral adrenalectomy is recommended for MEN2 patients. There is a high rate of recurrence than in sporadic cases. Follow up for a long duration after surgery is needed. Most patients should have annual biochemical screening.

References

  1. 1.0 1.1 National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_25_toc
  2. Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM; et al. (2017). "Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas". J Clin Endocrinol Metab. 102 (4): 1122–1132. doi:10.1210/jc.2016-3829. PMID 28324046.
  3. 3.0 3.1 Goldman 2011, pp. 327
  4. Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC; et al. (2010). "Trends in adrenalectomy: a recent national review". Surg Endosc. 24 (10): 2518–26. doi:10.1007/s00464-010-0996-z. PMID 20336320.
  5. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G (2001). "Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center". J Clin Endocrinol Metab. 86 (4): 1480–6. doi:10.1210/jcem.86.4.7392. PMID 11297571.